CIK 0001503802
- Non-accelerated filer
- Smaller reporting company
Karyopharm Therapeutics Inc.
Sign in to watch- Tickers
- KPTI KPTIQ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 263931704
- Phone
- +1 617-658-0600
- Business address
- 85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA, 02459
Securities
- KPTI Common stock Nasdaq
- KPTIQ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,135
- in 3 filings
Net −$2,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-25 | Frenkel Ran EVP, Chief Dev. Officer | Grant or award | +22,013 | 104,439 | ||
| 2021-02-25 | Frenkel Ran EVP, Chief Dev. Officer | Grant or award · Stock Option (right to buy) | +59,968 | 59,968 | ||
| 2021-02-25 | DEMAREE JOHN Chief Commercial Officer | Grant or award | +15,849 | 23,995 | ||
| 2021-02-25 | DEMAREE JOHN Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +43,177 | 43,177 | ||
| 2021-02-25 | Shacham Sharon President & CSO | Grant or award | +57,200 | 920,152 | ||
| 2021-02-25 | Shacham Sharon President & CSO | Grant or award | +57,200 | 718,826 | ||
| 2021-02-25 | Shacham Sharon President & CSO | Grant or award · Stock Option (right to buy) | +153,500 | 153,500 | ||
| 2021-02-25 | Shacham Sharon President & CSO | Grant or award · Stock Option (right to buy) | +153,500 | 153,500 | ||
| 2021-02-25 | Kauffman Michael Chief Executive Officer | Grant or award | +57,200 | 718,826 | ||
| 2021-02-25 | Kauffman Michael Chief Executive Officer | Grant or award | +57,200 | 920,152 | ||
| 2021-02-25 | Kauffman Michael Chief Executive Officer | Grant or award · Stock Option (right to buy) | +153,500 | 153,500 | ||
| 2021-02-25 | Kauffman Michael Chief Executive Officer | Grant or award · Stock Option (right to buy) | +153,500 | 153,500 | ||
| 2021-02-18 | Shah Jatin EVP, Chief Medical Officer | Sale | −1,186 | $14.83 | $18K | 51,791 |
| 2021-02-18 | Frenkel Ran EVP, Chief Dev. Officer | Sale | −2,887 | $14.83 | $43K | 46,126 |
| 2021-02-18 | Shacham Sharon President & CSO | Sale | −9,495 | $14.83 | $141K | 776,452 |
| 2021-02-18 | Shacham Sharon President & CSO | Sale | −9,495 | $14.83 | $141K | 575,126 |
| 2021-02-18 | Kauffman Michael Chief Executive Officer | Sale | −9,495 | $14.83 | $141K | 575,126 |
| 2021-02-18 | Kauffman Michael Chief Executive Officer | Sale | −9,495 | $14.83 | $141K | 776,452 |
| 2021-02-15 | Shah Jatin EVP, Chief Medical Officer | Exercise or conversion | +4,850 | 52,977 | ||
| 2021-02-15 | Shah Jatin EVP, Chief Medical Officer | Exercise or conversion · Restricted Stock Units | −4,850 | 9,700 |
Page 17 of 29 · 570 trades